Cortex Pharmaceuticals, Inc. Announces Appointment of Two

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors; Expands Board to Five Members

GLEN ROCK, N.J., Sept. 4, 2014 (GLOBE NEWSWIRE) -- Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"), a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression as well as obstructive, central and mixed sleep apnea, announces that James E. Sapirstein and Kathryn MacFarlane have joined the Board of Directors of the Company as independent directors. Both have distinguished careers in the biopharmaceutical industry and bring a depth and variety of professional experiences to the Cortex Board of Directors.

James E. Sapirstein, RPh., M.B.A., has been the Chief Executive Officer and director of ContraVir Pharmaceuticals, Inc., a public company, since March 20, 2014. Prior to joining ContraVir Pharmaceuticals, Inc., Mr. Sapirstein served as the Chief Executive Officer and a Director of Alliqua Biomedical, Inc. He is considered a start-up and turnaround specialist, with 30 years of pharmaceutical and biotechnology industry experience. He was a founder, Chief Executive Officer, President and a member of the Board of Directors of Tobira Therapeutics, Inc. from October 2006 to April 2011. He has launched several HIV/AIDS agents worldwide. Mr. Sapirstein was with Bristol-Myers Squibb, where he served as the Head of the International HIV business at Bristol-Myers Squibb, as well as working in its Infectious Disease marketing teams. In 2002, he accepted the position of Executive Vice President for Serono Laboratories, where he led a team of over 100 professionals in the HIV and pediatric growth hormone business. He has held positions at Gilead Sciences, where he was responsible for the product Viread®, as well as Bristol-Myers Squibb, Hoffmann-LaRoche Ltd. and Eli Lilly and Company. He serves as a member of the Advisory Board at MusclePharm Corp., and is a member of the Board of Directors of Clinical Supplies Management, Inc. He currently serves as an Advisory Board Director at the Fairleigh Dickinson School of Pharmacy.  He has also previously served as a Director of BioNJ and BIO's Emerging Company Board.  Mr. Sapirstein received his Pharmacy degree from the Ernest Mario School of Pharmacy at Rutgers University, and his Masters of Business Administration degree from Farleigh Dickinson University.

Kathryn (Katie) MacFarlane, Pharm.D., has over 25 years of experience in the pharmaceutical industry, with expertise in marketing, new product planning, and commercialization. Ms. MacFarlane is currently an owner and Managing Partner of SmartPharma LLC, a pharmaceutical consulting firm specializing in commercial consulting for emerging pharmaceutical companies. She also serves as the Chief Commercial Officer at Agile Therapeutics, Inc., where she played an integral role in two financing rounds and the recent IPO. Her expertise includes market assessment and commercial planning for products in development as well as evaluating products for licensing or acquisition. Her experience spans multiple therapeutic areas including Women's Health, CNS, Cardiology, Vaccines, and Dermatology. Before joining Agile Therapeutics, Ms. MacFarlane served as President and Chief Executive Officer at Xintria Pharmaceutical Corporation from 2006 through 2007. Ms. MacFarlane served as Vice President of Women's Health and New Product Planning at Warner Chilcott from 2001 through 2006. Ms. MacFarlane had responsibility for the launches of Lipitor ® , Celexa ® , and Loestrin ® 24. In 1999, she was named a Distinguished Alumna, and in 2012, she was named the Eaton Entrepreneur of the Year by the Purdue University School of Pharmacy. She has completed a Postdoctoral Fellowship in Industrial Pharmacy Practice with Rutgers University and Hoffmann-LaRoche. Ms. MacFarlane currently serves on the Purdue University School of Pharmacy Dean's Advisory Council and is a Founding Member and Advisor to IPhO. She also serves on the Board of Directors for INMED Partnerships for Children, an NGO dedicated to providing food security and health services to women and children. Ms. MacFarlane received her Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees from Purdue University.  

Cortex Executive Chairman and CEO, Arnold S. Lippa, Ph.D. stated, "We are delighted to have James Sapirstein and Katie MacFarlane join the Board of Directors of Cortex as part of our continuing efforts to restructure, recapitalize and rebuild the Company. Having worked with or collaborated with each of them in the past, I am confident of the value they will bring to the Company. We are pleased to welcome them to the Board and look forward to their thoughtful contributions."

About Cortex Pharmaceuticals, Inc.

Cortex Pharmaceuticals, Inc. is a biopharmaceutical company currently engaged in the discovery and development of drugs for the treatment of respiratory disorders. Drug candidates are currently derived from two platforms, as described below. 

The first platform is a class of compounds known as ampakines that act as positive allosteric modulators of AMPA glutamate receptors. Several ampakines in both oral and injectable form are being developed by Cortex for the treatment of drug induced respiratory depression caused by opiates and anesthetics. In preclinical and clinical studies, such drugs have shown preliminary efficacy in central sleep apnea and restored normal respiration without altering the analgesic effects of opiates or the anesthetic effects of drugs such as propofol. The Company's compounds belong to a new generation of ampakines that do not display the undesirable side effects displayed by previous compounds. 

The second platform is the class of compounds known as cannabinoids, in particular, dronabinol. In a double-blind, placebo-controlled, dose-ascending Phase 2A clinical study conducted by the Company, dronabinol significantly improved measures of sleep apnea in a group of patients with obstructive sleep apnea. A larger 120 patient, double-blind, placebo-controlled Phase 2B study is currently being conducted by the University of Illinois and is being funded by the National Institutes of Health.

Additional information about Cortex and the matters discussed herein can be obtained on the Company's web-site at www.cortexpharm.com or in the Company's filings on EDGAR at www.sec.gov .

Special Note Regarding Forward-Looking Statements :   Certain statements included or incorporated by reference in this news release, including information as to the future financial or operating performance of the Company and its drug development programs, constitute forward-looking statements. The words "believe," "expect," "anticipate," "contemplate," "target," "plan," "intend," "continue," "budget," "estimate," "may," "schedule" and similar expressions identify forward-looking statements. Forward-looking statements include, among other things, statements regarding future plans, targets, estimates and assumptions. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Many factors could cause the Company's actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, the Company. Due to these various risks and uncertainties, actual events may differ materially from current expectations.  Investors are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Forward-looking statements are made as of the date of this press release and the Company disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or results or otherwise.

Company Contact: Jeff Margolis Vice-President and Secretary Telephone: (917) 834-7206 E-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 18

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 76

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Inventor Launches Handy Solution for Kids' Car Sickness

Updated Category News Views 5

A Fresh Take on an Age-Old Problem Just when you thought the universe had thrown all it could at beleaguered parents, here comes a nifty little accessory tackling those dreaded uphill battles with kids and car rides. Some bright spark from Middleburgh, New York, sick of scrubbing car seats and clothing every other road trip, came up with a clever little invention named...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 73

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 56

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
AppLovin Faces Legal Heat: Investors on Edge Today

Updated Category News Views 43

AppLovin's Day of Reckoning: Investors Take Note Ever find yourself caught in a whirlwind of corporate promises that slide into disappointment? Well, buckle up, because that's exactly where AppLovin finds itself today. They've stirred up a storm with investors over some questionable hyperbole about their artificial intelligence tools and ad services. Missteps and Market...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 16

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading

Top 5 Most Recently Viewed Articles

PriceSmart Achieves Strong First Quarter Results and Expansion Plans

Updated Category News Views 229

PriceSmart Reports Impressive Growth in First Quarter of Fiscal 2026 PriceSmart, Inc. (NASDAQ: PSMT), with a presence across multiple regions, has announced substantial financial results for the first quarter of fiscal 2026, highlighting their ongoing growth and expansion strategies. The recent quarter ended on November 30, 2025, and the figures reflect a robust upward...

Continue Reading
Discover the New Belleza Community with Model Homes in California

Updated Category News Views 400

Exciting New Community in California Belleza at Lakeview is thrilled to announce the opening of their model homes, marking a significant step forward in the development of a brand new community in California. This community, designed with precision and style, invites potential homeowners to explore two stunning model homes, set to open soon for tours. Homebuyers are in...

Continue Reading
Bullish Nasdaq Signals Strong Potential for Long Investments

Updated Category News Views 89

Understanding Nasdaq's Recent Performance Recent market movements have highlighted a robust resurgence for bullish traders as they confidently regain control of their positions. The gains witnessed were particularly notable as the market showed resilience in defending critical support levels. Nasdaq's Bullish Technical Indicators As we explore the Nasdaq index, it becomes...

Continue Reading
Zero Homes Expands Services for Energy-Efficient Solutions

Updated Category News Views 123

Zero Homes Launches Comprehensive Services Across Colorado Zero Homes, a pioneering startup focused on digital solutions for home electrification, has announced its comprehensive statewide services tailored for every homeowner in Colorado. With its innovative approach, Zero Homes aims to guide residents in tapping into the newly established Colorado Home Energy Rebate...

Continue Reading
United Community Bank Foundation Commits $350,000 for Relief Aid

Updated Category News Views 107

United Community Bank Foundation's Commitment to Relief Efforts In the wake of the severe devastation caused by Hurricane Helene in the southern regions, the United Community Bank Foundation has stepped forward with a significant pledge. They are dedicating a remarkable amount of $350,000 to support local nonprofits that are actively engaged in the recovery and assistance...

Continue Reading